Fig. 6

Human Daoy MB xenografts. a PET/CT images of representative CTR (n = 6), SuFu WT (n = 6), and SuFu K321/457R (n = 8) mice showing tumour FDG (F-18-fluorodeoxyglucose) uptake at 41 days after implantation. ROI (region of interest) drafts the tumour mass. Significant differences were observed between SuFu WT and SuFu K321/457R mutant mice. U urinary bladder, M femoral muscle. b Graphic representation of SUV (standard uptake value). For each tumour, the SUV as mean tumour FDG uptake normalised for animal body weight was calculated. Significant difference in tumour FDG uptake was observed between SuFu K321/457R and SuFu WT mice. *P < 0.05, SuFu WT versus CTR; **P < 0.05, SuFu K321/457R versus SuFu WT. c Images of xenografted NOD/SCID mice with bilateral MB xenograft tumours. Tumour volume in SuFu K321/457R mutant mice is visually bigger than SuFu WT (scale bars = 5 mm). d Tumour volumes were monitored over time by caliper measurements at the indicated times. *P < 0.01, SuFu WT versus CTR; **P < 0.01, SuFu K321/457R versus SuFu WT. e Tumour volumes were measured post explantation. *P < 0.01, SuFu WT versus CTR; **P < 0.01, SuFu K321/457R versus SuFu WT. f Immunohistochemistry of Ki67 and Gli1 stainings. Scale bars indicate 50 µm. g Quantification of Ki67 and Gli1 stainings from immunohistochemistry. *P < 0.01, SuFu WT versus CTR and **P < 0.01, SuFu K321/457R versus SuFu WT. h Western blot analysis shows protein expression levels. Error bars indicate SD. P-values were determined using Mann–Whitney U-test